Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122351 | 1.00 | KMT2A (0.47) | KMT2APKMHSD11B1NFE2L2PTGS1 | |
| SCHEMBL29259613 | 0.82 | NFE2L2 (0.50) | KMT2APKMHSD11B1NFE2L2PTGS1 | |
| SCHEMBL950718 | 0.80 | HSD17B10 (0.52) | NFE2L2PTGS1FBP1ALOX5PTGS2 | |
| SCHEMBL28849917 | 0.80 | KMT2A (0.49) | KMT2APKMHSD11B1NFE2L2PTGS1 | |
| SCHEMBL950722 | 0.80 | HSD17B10 (0.52) | NFE2L2PTGS1FBP1ALOX5PTGS2 | |
| SCHEMBL28849918 | 0.80 | KMT2A (0.49) | KMT2APKMHSD11B1NFE2L2PTGS1 | |
| SCHEMBL1323494 | 0.78 | KMT2A (0.47) | KMT2APKMHSD11B1NFE2L2PTGS1 | |
| SCHEMBL5729623 | 0.78 | CYP2A6 (0.50) | KMT2ANFE2L2PTGS1MEN1FBP1 | |
| SCHEMBL5729627 | 0.78 | CYP2A6 (0.50) | KMT2ANFE2L2PTGS1MEN1FBP1 | |
| SCHEMBL8414375 | 0.78 | APP (0.41) | NFE2L2PTGS1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379508-B9 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-02-09 | — | — | EP | disclosed |
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| EP-1379508-B1 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7772262-B2 | Substituted benzoylguanidines, method for production and use thereof as medicament or diagnostic and medicament comprising the same | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-20070270414-A1 | SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-22 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1188755-B1 | ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1379508-A4 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6723722-B1 | BLOOD COAGULATION FACTOR X INHIBITORS; ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| EP-1379508-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6646009-B2 | Use against proliferative disorders including cancer, and as a radioprotective compound for normal cells from ionizing radiation | Temple University — Of Commonwealth System of Higher Education | 2003-11-11 | — | — | US | disclosed |
| US-20020165412-A1 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | ONCONOVA THERAPEUTICS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002067865-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1188755-A1 | ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270414-A1 | SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME | SLC9A1, SLC9B2, SLC9A2 | KMT2A 1898/4885PKM 2010/4885HSD11B1 2159/4885 |
| US-20020165412-A1 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | HCCS, NAT1, ARSA | KMT2A 2811/4885PKM 3419/4885HSD11B1 2877/4885 |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | KMT2A 922/4885PKM 4094/4885HSD11B1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.